Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Etoricoxib/Betamethasone FDC vs Individual Components
NCT07454369Phase 1Completed
- Sponsor
- Laboratorios Silanes
- Start
- Oct 2022
- Primary completion
- Nov 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of etoricoxib and betamethasone in pain and inflammation, sponsored by Laboratorios Silanes. Primary endpoints: Maximum Plasma Concentration at 72 hours, Area Under the Curve from time zero to the last measurable concentration at 72 hours and 3 more. Started Oct 2022; status: completed.
02
Drugs
etoricoxibbetamethasone
03
Conditions
paininflammation
Beyond the preview
Go deeper on NCT07454369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07454369.